Stuart Lowe, Head of Advanced Therapies, TTP | Onyx Live | Advanced Therapies 2026

CAR-T therapies can exceed $1 million per patient when manufacturing and hospital care are tallied. Just 1 in 5 eligible patients ever gets one.

A single CAR-T dose still takes up to 33 days to manufacture, at $170,000–$220,000 per batch.

TTP, the Cambridge product-development firm, has built its advanced therapies practice around a single bet: that the manufacturing bottleneck can be solved without forcing biotechs to rip out and replace their existing process. Cellular Origins – the cell-and-gene-therapy spin-out born out of TTP – now embodies that thesis with its Constellation platform, using autonomous mobile robots and automated tube welding to interconnect third-party instruments into sterile, GMP-compliant 24/7 production lines. Recent Cellular Origins milestones include:

• Strategic collaboration with Johnson & Johnson (June 2025) to develop end-to-end automated platforms for autologous CAR-T manufacturing
• £1 million Innovate UK Smart Grant (July 2025) with the Cell and Gene Therapy Catapult and Resolution Therapeutics
• $40 million oversubscribed Series A closed in December 2025, led by Johnson & Johnson Innovation – JJDC

At Advanced Therapies 2026, Onyx sat down with Head of Advanced Therapies, Stuart Lowe, to find out more.

A special thanks to our Onyx Live sponsors:

HUMPHREYS LAW – a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/

Panacea – AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/